Overview

    The Pelvic Floor Disorders Registry (PFDR), the American Urogynecologic Society's (AUGS) national patient registry, is a multi-centered prospective cohort of patients undergoing treatment for pelvic organ prolapse (POP) to evaluate the effectiveness, quality of life and safety associated with both surgical therapy (transvaginal/transabdominal native tissue repair, transvaginal mesh repair and sacrocolpopexy) and non-surgical management (pessary). The PFDR is designed to collect both provider and patient reported outcomes through broad participation by physicians providing treatment for POP.

    The PFDR is a web-based platform designed to collect, store and analyze both provider and patient reported outcomes through broad participation from specialists and generalists performing surgery for prolapse. The Registry will also provide a framework for stakeholders in cooperation with AUGS to conduct research to improve knowledge in the field.

    The primary objectives of the registry are to:

    • Evaluate the effectiveness, quality of life and safety associated with surgical options (transvaginal/transabdominal native tissue repair, transvaginal mesh repair and sacrocolpopexy) for POP
    • Assess the effectiveness and quality of life associated with non-surgical management (pessary) for POP
    • Provide a framework for clinical studies to be conducted within the registry, including industry-sponsored studies required to fulfill the FDA’s request for postmarket surveillance for transvaginal mesh for POP
    • Allow healthcare providers to track surgeon volume, patient outcomes, and quality measures for quality improvement activities and fulfill upcoming Centers for Medicaid and Medicare Services (CMS), Physician Quality and Reporting Systems (PQRS) and maintenance of certification requirements

    The secondary objectives of the registry are to:

    • Identify modifiable and non-modifiable risk factors associated with complications and reduced effectiveness of PFD treatments
    • Capture comprehensive data that includes those elements required by the FDA’s requirement for postmarketing surveillance of transvaginal mesh use for POP
    • Function as resource for additional PFD research, whereby stakeholders and participants may propose and conduct analyses of registry data (as approved by registry’s Scientific Committee) and in cooperation with AUGS

    In the future, the registry objectives may be expanded to include evaluation of treatment for SUI without concurrent POP and potentially other PFDs.
     

    Support the PFDR

    The PFD Registry is thankful for the generous support of the PFD Registry provided by:

    ACell

    ASTORA Women’s Health

    Boston Scientific

    Coloplast

    Interested in supporting the PFD Registry? Please contact pfdregistry@augs.org to discuss potential partnership opportunities.


    logo.jpg

     

    1100 Wayne Avenue, Suite 670
    Silver Spring, MD 20910
    P: 301-273-0570 | F: 301-273-0778
    info@augs.org

     

    Copyright © 2017 American Urogynecologic Society. All Rights Reserved.